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Cancer remains a worldwide problem, and so requires solutions. Research on 
cancer has been progressed extensively, but no perfect solution exists, despite 
the numerous diagnosis and treatment methods. Biomarkers are being used as 
a part of solutions against cancer, and research to discover new markers is 
being proceeded using many methods. In such research, bioinformatics 
methods can be used to find specific targets, with networks and gene ontology 
analysis relating to characteristics of cancer. Cancer has different features, and 
needs different approaches pathologically; thus, the present research was 
performed on breast cancer alone. First, database was constructed specializing 
in cancer and biomarkers for efficient management of data and for a firm 
foundation of analysis. Data required for the database construction were 
brought from many public repository such as NCBI, NCI, and UniProt. These 
data were processed by Html, Java, JavaScript, MySQL and JSP as several 
programming languages to fit their purposes. Second, cancer network was 
formed by utilizing the collected data. It was produced by mapping the cancer 
gene ID in protein interaction data, and inspected for power-law distribution 




specific network produced showed such a distribution, so the existence of the 
hub was ascertained, and reflecting on the characteristics of the graph 
determined the rank of hub genes. Accordingly, by calculating the network 
parameters such as degree distribution, betweenness centrality, and stress 
centrality, the top 150 hub genes were obtained. The following analysis 
filtered for specific GO terms reflecting on the characteristics of breast cancer 
through GO enrichment analysis utilizing 2,902 genes forming cancer 
network and breast cancer–related genes. By adjusting these specific GO 
terms to 2,902 genes of the cancer network, a gene list was obtained that is 
involved in general cancer with has breast cancer-specific GO terms. In the 
last step of the analysis, target genes were obtained through Venn diagram 
analysis by PPI network with GO enrichment analysis and target candidates, 
and results for five clinical markers were referred to. As a result, 34 genes 
with similar traits as clinical markers in PPI network and GO were selected as 
targets, and they are anticipated to be utilized primarily in selection of the 
next breast cancer marker. In addition, if such methods could filter candidates 
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CHAPTER  I. 
INTRODUCTION 
 
1.1 Overview of cancer 
Cancer is a major problem worldwide and accounts for one-quarter of 
deaths in the U.S. (Siegel et al., 2013). The situation in South Korea is no 
different: according to the National Cancer Information Center, the death rate 
from cancer declined 2.7% from 2002 to 2010, yet the incidence rate of 
cancer was 3.3% annually from 1999 to 2010 (Jung et al., 2013). Though the 
major cancers are different among races or nations, the core mechanism 
through which cancer cells form and lead to death are similar. Cancer is a 
disease where the expression and biochemical functions of genes are inhibited 
by genetic dysregulations from DNA recombination and point mutations. 
Therefore, we need to understand the effect and mechanisms of the variation 
and other regulatory factors of genes (Bishop, 1987). Cancer is a genetic 
disease in which the accumulation of genetic damage, activation of oncogenes 
and deactivation of tumor suppressor genes causes normal cells to become 
malignant cells (Anderson et al., 1992; Vogelstein and Kinzler, 2004). 
Therefore, it is important that the concepts, general features, and roles of 
proto-oncogenes, oncogenes, and tumor suppressor genes are understood in 
carcinogenesis. Importantly, genes that accumulate mutations and genes that 
help cancer cells metastasize need to be covered (Yokota, 2000). In this 
chapter, the general characteristics of cancer, the roll of cell cycle in cancer, 




1.1.1 General characteristics of cancer 
Two major differences differentiate cancer from other genetic diseases. 
One is that cancer is often caused by mutation in somatic cells, and the other 
is that cancer involves the accumulation of mutations (Vogelstein and Kinzler, 
1993). Cancer cells have numerous different features compared to normal 
cells, including the potential for infinite proliferation and cell divisions, and 
that can be metastasize to other locations in the body. These features may not 
be applicable to all cancers, but they are general features that can be applied 
to many cases (Hanahan and Weinberg, 2000). See Table 1.1. The first feature 
of cancer cells is self-proliferation that does not rely on growth factor 
signaling. ECM (Extracellular Matrix) refers to the structure surrounding cells 
within the body to which they attach; changes in the material and structure 
affect the processes of metastasis and division (Watt, 1986). Cells grow by 
growth factor signaling mediated by cell-cell communication. However, if a 
mutation occurs to a gene or receptor coding a growth regulator, cancer cells 
are likely to form (Lukashev and Werb, 1998). The second feature of cancer 
cells is that they are not regulated by the signaling of tumor suppressor genes 
such as TP53. If a dysregulation occurs to differentiation and proliferation 
signaling in cases such as DNA damage, p53 mediated the repair mechanism 
is activated to start repair of the cells. Failure to repair can occur, causing p53 
to induce apoptosis of the cells to prevent other mutations (Yonish-Rouach et 
al., 1991). However, because p53 is deactivated by mutation in tumor cells, 
they are unable to cause apoptosis; this leads to transition into a malignant 
tumor by increasing genetic instability, accumulation of mutations, and the 
possibility of genetic rearrangements. The loss of apoptotic function by 
mutated p53 is known to contribute significantly to the survival of tumor cells 
(Lane, 1992). The third feature of cancer cells is the evasion of the normal 




through normal embryonic development and in healthy adults. Additionally, 
apoptosis occurs naturally in untreated malignant tumors, and seems to have 
an effect on the degeneration of certain types of tumors. It shows that 
apoptosis could affect both the biological degeneration and atrophy of various 
tissues and organs, and that this mechanism can be induced by harmful 
changes within the body (Kerr et al., 1972). Multicellular animals control the 
number of cells by maintaining a balance between cell proliferation and 
apoptosis; tumor cells are resistant to apoptosis, the resistance is causing 
various diseases including cancer (Thompson, 1995). Therefore, the apoptosis 
mechanism without protectional functions such as cell removal is the main 
cause of disease (Vaux and Korsmeyer, 1999). The fourth feature of cancer 
cells is infinite replication. A specialized functional structure called the 
telomere, which has short repeating DNA sequences, exists in the terminal 
part of eukaryotic chromosomes. Telomeres are fundamental to the 
duplication and stabilization of chromosomes (Blackburn and Szostak, 1984). 
The enzyme telomerase interferes in the length maintenance and duplication 
of the telomere (Morin, 1989). Normal somatic cells lose telomeric DNA 
sequences through incomplete duplication or other erosions of chromosome 
terminals, and at a certain point, go through the aging process due to a lack of 
telomerase activity. However, in immortalized cells such as cancer cells, the 
telomere is maintained by activation of telomerase to evade the aging process 
(Harley, 1991). Telomerase activation during immortalization is confirmed by 
the result of an experiment showing that telomerase is suppressed in most 
normal cells in tissues, but reactivated in most cells in malignant tumors (Kim 
et al., 1994). Therefore, for cancer cells to be immortal, the length of telomeres 
must be maintained, and the reactivation of the telomerase is crucial in this 
process (Bryan et al., 1995). The fifth feature of cancer cells is the ability to 
induce angiogenesis. Blood vessels are composed of endothelial cells 




tissues. When an organism matures, new vessels are only formed through 
angiogenesis, a process controlled by pathological situations such as the 
curing of wounds and growth of tumors. The growth of new blood vessels is 
particularly fundamental in the growth and metastasis of tumors (Hanahan and 
Folkman, 1996): if the proper construction of vasculature is interrupted, the 
tumor cells either undergo necrosis (Brem et al., 1976) or apoptosis (Parangi 
et al., 1996). If angiogenesis is insufficient, a tumor is not supplied with the 
nutrition necessary for survival, and is unable to grow to a certain extent or 
undergo metastasis (Carmeliet and Jain, 2000). The sixth feature of cancer 
cells is metastasis. Unlike normal cells that do not invade non-resident tissues 
in the body, cancer cells are able to invade and spread to distant tissues from a 
primary tumor source. While most facts regarding the development of 
metastasis for cancer cells are uncertain, the basic process can be understood. 
Metastasis is composed of consecutive processes such as formation of primary 
tumors, proliferation / angiogenesis, separation / invasion, circulation, 
extravasation, and colonization (Fidler, 2003). Metastasis accounts for 90% of 
deaths caused by cancer occurs when tumor cells adjust to the delicate 
environment of tissues far from the primary tumor; these adjustments include 
being able to selectively choose features advantageous for overcoming 
resistance to the environment, gained through heterogeneity of cancer cells 
that have lost control of genetic stability (Gupta and Massague, 2006).  
 
1.1.2 Cell cycle and cancer 
 The general features of cancer mentioned above describe the 
uncontrolled proliferation cells. They gain the ability for unregulated cell 
proliferation through damage to the genes controlling their life cycle (Sherr, 
1996). Therefore, the relationship between cancer and the cell cycle is 




growth and division; it comprises multiple phases: G1, S, G2, and M. At a 
certain point in the cell cycle, protein complexes of cyclin and CDKs (Cyclin 
Dependent Kinases) exist that have important roles in the various different 
processes of the cell cycle (Morgan, 1997). First, the cyclin D / CDK 4, 6 
complex controls the cell cycle during G1, and at R point (Restriction point) 
at the end of G1, this complex decides whether to continue the cell cycle or 
shift to interphase (G0). The cyclin E / CDK 2 complex serves an important 
role in shifting from G1 to S phase if the R point has been passed. Afterwards, 
cyclin A forms a complex with CDKs 1 and 2 to control completion of S 
phase and G2 phase. Lastly, if M phase starts, the cyclin B / CDC 2 (CDK 1) 
complex induces mitosis (Pardee, 1974; Nurse, 2000; Hochegger et al., 2008). 
A checkpoint exists as a biochemical pathway to control mechanisms such as 
DNA replication and separation of chromosomes by regulating the timing of 
each phase. The G1 checkpoint prevents the replication of damaged DNA in S 
phase by halting the cell cycle. The G2 checkpoint serves to inspect the 
replication of S phase, and the M phase checkpoint ensures that adherence of 
chromosomes to the spindle fibers during mitosis was completed normally. If 
there are any problems with checkpoint functions, genetic stability is inhibited, 
thus increasing the possibility of mutations that contribute to cancer (Hartwell 
and Weinert, 1989; Hartwell and Kastan, 1994; Elledge, 1996). This process 
is shown in Figure 1.1. 
 
1.1.3 Virus and cancer 
Reviewing the general properties of cancer, another important 
relationship exists between viruses and cancer. Oncoviruses with DNA or 
RNA molecules manifest continuously in transformed cells to maintain this 
altered feature in offspring cells (Martin, 1970). The diversity of proteins 




cytoplasm, and cell membrane (Bishop, 1985). Additionally, tumor viruses 
indirectly induce immunosuppressive reactions, and can directly transform 
protein expression in host cells to contribute to the development of tumors 
within the body (Hausen, 1991). Tumor viruses include HPV (Human 
Papillomavirus), HBV (Hepatitis B Virus), EBV (Epstein-Barr Virus), and 
HIV (Human Immunodeficiency Virus); we will briefly take an in-depth look 
into EBV and HIV next. EBV was first discovered by electron microscopy of 
cells cultured from Burkitt lymphoma (Epstein et al., 1964). A gene encoded 
by EBV induces the transformation of B cells by altering gene transcription 
and activating the cells’ signaling pathway structurally. Additionally, EBV 
utilizes the biological features of normal B cell division to avoid elimination 
by the host immune system. Transplant patients could be vulnerable to EBV 
infection by proliferation of transformed B cells. Likewise, EBV infection 
affects the etiology of various other lymphocytes and epithelial in malignant 
tumors (Young and Rickinson, 2004). It was also revealed that HIV, another 
important tumor virus, tends to increase the risk of cervical legions (Chirenje, 
2004), and Hodgkin’s lymphoma in people with HIV / AIDS (Bigger et al., 
2006). 
 
1.1.4 Cancer in epigenetics 
 Taking a look at recent cancer research trends, there is an abundance of 
research from the perspective of epigenetics. This starts from the recognition 
that mutations of various genetic information contained within cells cannot be 
completely explained at the level of the DNA sequence. Cancer epigenetics 
mainly deals with the mechanics of DNA methylation, genomic imprinting, 
and histone modification and their effects on cancer (Finberg and Tycko, 
2004). DNA methylation (5-methylcytosine) in the promoter of mammals 




Laird, 1999). Promotor-associated CpG islands in special cases such as X-
chromosome inactivation and gene silencing suppresses expression. From this, 
we are able to appreciate that DNA methylation plays an important role in the 
control of gene expression, and this mechanism is important in cancer as well 
(Birs, 2002; Jones and Baylin, 2002). Hypomethylation and hypermethylation 
occur in cancer-related DNA methylation. The former affects the 
overexpression of oncogenes and genetic stability, while the latter affects the 
suppression of expression of tumor suppressor genes to contribute to the 
formation of tumors (Ehrlich, 2002). Histone deacetylation and histone 
methylation contribute to abnormal gene silencing mechanisms of specific 
tumor suppressor genes in tumor cells with aberrant DNA methylation 
(Bachman et al., 2003; Esteller, 2007). Altogether, gene silencing is 
controlled by the interactions between DNA methylation, histone 
modification, and nucleosomal remodeling, with anomalies in this process 





1.2 Oncogenes and proto-oncogenes 
 Oncogenes and proto-oncogenes are genes involved in the process of 
carcinogenesis. In this section, we will first cover the general features of 
oncogenes, and specifically the most well-known oncogenes: the protein 
kinase and Ras gene families. For normally functioning genes to undergo 
carcinogenesis, accumulated mutation needs to occur to transform them into 
oncogenes. A simple diagram is shown in Figure 1.2. Normal genes with the 
potential to transform into oncogenes are called proto-oncogenes, and the 
proteins that they code for normally perform functions related to the control of 
cell growth and the cell cycle. The mechanism of activation for a proto-
oncogene to become an oncogene can be divided into three parts: mutation, 
gene amplification, and gene rearrangement. These three mechanisms bring 
about changes in the structure or expressed level of the oncogenes, and are 
activated into oncogenes by increasing the survival rate of cells and providing 
a growth advantage. The activation of oncogenes through mutation in the 
coding region brings about changes such as an increase in the protein’s 
activation, while gene amplification leads to the overexpression of the normal 
protein. Additionally, if rearrangement such as inversion or translocation of 
the chromosome occurs, normal proteins could be overexpressed or abnormal 
recombined proteins could induce the activation of oncogenes, ultimately 
leading to carcinogenesis. The mechanisms of action for oncogenes are shown 
in Figure 1.3 (Carlo, 2008; Alberts et al., 2009). 
 
1.2.1 Features of oncogenes 
 Proto-oncogenes function normally until they are activated as 
oncogenes. Therefore, we must discuss how normal proto-oncogenes function 




mutated from growth factors. V-sis is a viral oncogene extracted from SSV 
(Simian Sarcoma Virus). Comparing the sequence of the p28sis protein 
created by this gene and PDGF (Platelet-derived Growth Factor) showed they 
have high homology. This revealed that v-sis is a result from the 
recombination of PDGF coding gene and virus (Doolittle et al., 1983). The 
signal secreted by PDGF activated in cancer cells affects the proliferation of 
the clone before expression of the tumor. Additionally, if consistent genetic 
changes are made, PDGF contributes to the formation of the tumor by 
creating an unstable cell environment (Andrae et al., 2008). Growth factor 
genes such as PDGF may lead to various diseases such as cancer (Aaronson, 
1991). Second, oncogenes can be transformed growth factor receptors. As 
previously mentioned, cancer cells are able to grow without relying on growth 
factor signals. Many growth factors and growth factor receptors are involved, 
and we will more closely explore EGFR (Epidermal Growth Factor Receptor). 
EGFR is a receptor for EGF (Epidermal Growth Factor) that is a tyrosine 
kinase among the EGF receptor family (ErbB family), including ErbB-2, 
ErbB-3, and ErbB-4 (Salomon et al., 1995). The ErbB receptors and 
associated ligands control intercellular functions such as growth, 
differentiation, survival and angiogenesis that take part in the mechanism of 
tumor progression (Normanno et al., 2006). Third, oncogenes can be mutated 
from the signal transducer. To send the mitosis signal from the growth factor 
receptor to the nucleus of cells, a complicated mechanism is required called 
signal transduction. Signal transducers functioning in this pathway can be 
separated into two groups of non-receptor protein kinases and GTP 
(Guanosine Triphosphate)-binding proteins. Non-receptor protein kinases are 
divided into subgroups of tyrosine kinases and serine / threonine kinases, 
while GTP-binding proteins are categorized into H-ras, K-ras, N-ras and Gsp, 
Gip according to their chemical features. If signal transducers are mutated into 




uncontrolled cell proliferation (Sevik, 2012). For instance, Src (Sarcoma), a 
tyrosine kinase, controls functions of cells such as adherence, invasion and 
movement; these functions can contribute to the process and metastasis of the 
tumor (Yeatman, 2004). Fourth, oncogenes can arise from mutations of 
transcription factors. APC (Adenomatous Polyposis Coli) is a tumor 
suppressor gene that combines with cadherin to affect cell adherence, and 
combines with Tcf-4 (Transcription factor 4) to induce the decomposition of 
β-catenin, which controls gene transcription (Munemitus et al., 1995; Morin et 
al., 1997). In most colorectal cancers, deactivation of APC by mutation is 
found, inducing the abnormal accumulation of β-catenin. This increases the 
transcriptional activation of genes, and ultimately contributes to tumor 
formation. In the abnormal APC pathway, c-Myc (cellular-Myc 
(Myelocytomatosis)), a transcription factor control gene, is overexpressed and 
plays an important role in the detection of abnormal activation of the APC 
pathway (He et al., 1998). Table 1.2 has categorized proto-oncogenes by their 
normally performed functions with examples. Two pivotal oncogenes 
mentioned above (protein kinase and Ras) will be explored in more detail. 
 
1.2.2 Representative oncogene: protein kinase 
 We will first review the protein kinase gene family, the core proteins of 
which participate in the signal transduction pathway and are found in mutated 
states in various diseases such as cancer (Schlessinger, 2000). The cell growth 
and mutation mechanisms used by mammals to interpret signal transduction 
are complicated, but some genes are known that control this process. Among 
them is the protein kinase gene family, one of the biggest gene families in 
eukaryotes. They play an important role in cell cycle control and signal 
transduction through phosphorylation. For instance, tyrosine protein 




producing specific combinations of parts of the protein including the SH2 (Src 
Homology 2) domain. The interaction within molecules of the phosphorylated 
tyrosine and the SH2 domain may also interfere with control of enzyme 
activation (Cantley et al., 1991).  An example of a protein kinase is the Abl 
gene: Abl produces a non-receptor tyrosine kinase within the nucleus. Abl 
(Abelson murine leukemia viral oncogene homolog) exists on chromosome 9 
and is activated as an oncogene through the formation of the Bcr-Abl fusion 
by gene translocation with BCR (Breakpoint Cluster Region) on chromosome 
22, leading to strong phosphorylation activation (Jensen and Hunter, 2001). 
Normally Abl induces the apoptosis of cells when their DNA is damaged; 
since the Bcr-Abl fusion exists within the cytoplasm, not the nucleus, the cell 
is able to evade DNA damage-directed apoptosis by this mechanisms. This 
mutation is common in acute leukemia (Vigneri and Wang, 2001). The 
protein kinase gene family exists in the cell membrane as either a 
transmembrane receptor or a signal transducer, or in the nucleus to interfere 
with control mechanisms of processes such as transcription, cell cycle, 
apoptosis, and differentiation. It controls signal transduction in eukaryotic 
cells and interferes with gene expression (Manning et al., 2002).  
 
1.2.3 Representative oncogene: Ras 
 The next crucial oncogene is the Ras (Rat sarcoma) family. The Ras 
family is activated as oncogenes through point mutations arising in specific 
codons; these mutations are discovered in various tumors such as colorectal 
cancer, lung cancer, and pancreatic cancer. This gene family codes similar 
proteins and include functional components of H-ras, K-ras and N-ras. Ras 
protein plays a pivotal role in stimulation and signal transduction of factors 
associated with cell growth and differentiation (Barbacis, 1987; Bos, 1989). 




connecting to GTP and deactivated by attaching to GDP (Guanosine 
Diphosphate). Stimulation of Ras occurs via signaling mediated by RTK 
(Receptor-tyrosine Kinase), and this stimulation or signal activates GEF 
(Guanine nucleotide-exchange factors) such as SOS (Son Of Sevenliss) 1/2 
and Ras-GRF (Ras-specific Guanine nucleotide-releasing Factor). Activated 
GEF stimulates Ras-GDF to induce them to form Ras-GTP. The activation 
signal is terminated when Ras-GTP is hydrolyzed into Ras-GDP through the 
GTP hydrolysis catalyst function of Ras-GAP (GTPase-activating Proteins). 
Suppressor genes such as SPROUTY and the ACK protein family delay the 
activation of SOS1/2 proteins to inhibit Ras activation mediated by RTK 
(Malumbres and Barbacid, 2003). The activation of Ras is controlled by 
complex processes; if mutation occurs to a specific codon of this gene (12, 61, 
and rarely 13 amino acids), the GTPase function of the Ras protein either 
decreases or is exterminated. Then, activated Ras-GTP does not transform 
into deactivated Ras-GDP and the mutated phenotype is continuous activation 
(Scheffzek et al., 1997). Ras interferes with various signaling pathways and is 
a pivotal oncogene necessary for the generation and maintenance of tumor 





1.3 Tumor suppressor genes (TSGs) 
 The tumor suppressor gene is another important factor participating in 
the carcinogenic mechanism by functioning as an antiproliferative signal 
transducer biochemically; biologically, they play an important role in the 
proliferation, differentiation, and apoptosis of cells. If mutation of a tumor 
suppressor gene occurs, this disables functions such as maintaining the 
number of cells, leading to diseases such as cancer (Weinberg, 1991). In this 
chapter, we will take a look at the general features of tumor suppressor genes 
and two the representative tumor suppressor genes (Rb and TP53). Tumor 
suppressor genes show different behavior from oncogenes. Oncogenes appear 
to be dominant, able to form tumors only if either of the alleles mutate; tumor 
suppressor genes appear to be recessive, able to form tumors only when both 
the alleles mutate. Even if one tumor suppressor gene is damaged, the other is 
able to produce normal protein. This is known as the ‘two-hit hypothesis’, 
which explains that if there is a genetic mutation, the tumor can only be 
induced through two mutations (Knudson, 1971). However, this hypothesis 
does not always apply to tumor formation by all tumor suppressor genes. 
Mutation in TP53 could function as a dominant negative, meaning that the 
protein produced by a mutated TP53 could inhibit the function of a normal 
protein from a non-mutated allele (Baker et al., 1990). Though there are 
exceptions, the two-hit hypothesis is important in explaining tumor formation 
involving tumor suppressor genes. Figure 1.4 and 1.5, respectively, explain 
the two-hit hypothesis and the differences in activation mechanisms of 





1.3.1 Features of TSGs 
 The maintenance of the number of cells plays an important role in 
survival, and tumor suppressor gene are controlled by proliferation, 
differentiation, and apoptosis of cells. Tumor suppressor genes are considered 
important in cancer because they are involved in functions such as cell cycle 
control, DNA damage detection and repair, degradation of protein, cell 
differentiation, and tumor angiogenesis (Sherr, 2004). Tumor suppressor 
genes can be categorized according to their functions: Table 1.3 shows 
examples of tumor suppressor genes and the functions of their respective 
proteins. First, tumor suppressor genes related to the cell cycle. p16INK4a 
combines with CDK4 to inhibit the activation of the CDK4 / cyclin D 
complex; it can also combine with Rb to function as a negative regulator of 
proliferation in normal cells. p16INK4a produces a negative feedback loop to 
control Rb with the suppression of proliferation (Serrano et al., 1993). 
Suppression of proliferation occurs when p16INK4a is overexpressed, inhibiting 
the phosphorylation of Rb and the function of the CDK4 / cyclin D complex 
to stop the cell cycle at the end of G1 phase (Lukas et al., 1995). To prevent 
indiscrete proliferation of cells, the functions of tumor suppressor genes 
p16INK4a and Rb are important. However, in many cases these two genes are 
deactivated by mutations in tumor cells and unable to suppress 
overproliferation of cells. Second, tumor suppressor genes that interfere with 
signal transduction. The genetic product of NF1 (Neurofibromatosis type 1), 
one of the genes causing neurofibromatosis type 1, causes GAP activation in 
the Ras signal transduction pathway. Protein produced by NF1 is fundamental 
for the accurate negative regulation of Ras of cells and enables the 
suppression of cell proliferation. This phenomenon can also be observed in 
the abnormal activation of Ras in tumor cells of malignant neurofibromatosis 




transcription. WT1 (Wilms Tumor 1) is a causal gene of the Wilms tumor and 
codes four zinc finger proteins that combine with the DNA of specific 
sequences such as EGR-1 (Early Growth Response protein 1). If WT1 does 
combine with specific DNA, it functions as a transcriptional suppressor in the 
NH2-terminus abundant with glutamine and proline. In tumor cells, the DNA 
binding domain of WT1 is deactivated, and could cause transcriptional 
suppression by WT1 (Madden et al., 1991). Fourth, tumor suppressor genes 
involved in cell adherence and metastasis. Problems with cell adherence affect 
carcinogenesis and the biological features of cancer. For instance, the genetic 
change shown in the cell adherence system with E-cadherin could cause 
several steps in carcinogenesis. Genes involved in cell adherence prevent the 
spread of cancer cells without cancer inhibition and play an important role in 
suppressing metastasis (Yoshida et al., 2000; Hirohashi and Kanai, 2003). 
Some genes with metastasis suppressing functions, called metastasis 
suppressors, generally code proteins involved in cell adherence and cell 
movement. The first metastasis suppressor gene to be discovered is NM23 
(Nucleoside diphosphate kinase A, also known as NME1). MKK4 (Mitogen-
activated protein Kinase Kinase 4), another metastasis suppressor, induces the 
death of cells to inhibit the last part of metastasis: colony formation (Steeg, 
2003). Fifth, tumor suppressor genes involved in DNA repair. Abnormality in 
the repair mechanism increases the mutation rate of genes, speeding up the 
development of cancer due to the accumulation of mutations (Loeb, 1991). A 
flaw in the repair mechanism contributes to the development of cancer by 
increasing the mutation rate within cells, potentially deactivating tumor 
suppressor genes and activating oncogenes by inducing a high mutation rate 
in other tumor suppressor genes and oncogenes, thus contributing to 





1.3.2 Representative TSG: Rb 
 Next, we examine two genes that are important tumor suppressor genes. 
The first gene is Rb (Retinoblastoma protein, also known as pRB, RB1), the 
causal gene of retinoblastoma. The product of this gene shows functional 
abnormalities in several cancers (Murphree and Benedict, 1984). Normal Rb 
is phosphorylated by CDK in the process of shifting from G1 to S phase, 
functioning as a transcriptional regulator. From the perspective of 
phosphorylation, this process is carried out such that Rb, which used to exist 
in a hypophosphorylated state becomes hyperphosphorylated at the end of G1, 
maintaining that state for the rest of G1 to lose phosphate in M phase 
(Weinberg, 1995). In the control of cell cycle and metastasis, the interactions 
of Rb, the transcription factor E2F, and the HDAC (Histone Deacetylation) 
enzyme are very important, and the mechanism functions as follows. When 
there is a growth factor signal, hyperphosphorylated Rb activates metastasis 
through genes such as E2F and HDAC to enable cell cycle to shift from G1 to 
S phase. If there is no growth factor signal, Rb is hypophosphorylated, 
forming a complex structure with E2F and HDAC to inhibit the interaction 
with metastasis factors and the expression of E2F target genes, thereby 
suppressing the expression of genes necessary for cell cycle progression (Zhu, 
2005). Also, the relationship between Rb and p53, another tumor suppressor 
gene, is important. The loss of function of Rb causes abnormal proliferation 
due to failure to control E2F and the activation of p53, which should suppress 
cell growth. Here, E2F directly binds with the MDM2 (Mouse Double Minute 
2 homolog)-p53 complex to activate the tumor suppressing protein, p14ARF’; 
this inhibits the degradation of p53. Through this mechanism, it is possible to 
understand the interaction of Rb and p53 in signal transduction as explained 





1.3.3 Representative TSG: TP53 
 Another important tumor suppressor gene is the aforementioned gene 
TP53 (Tumor Protein 53). The gene encodes for the phosphoprotein p53. 
Mutation of this gene is most frequently observed in almost cancers. The 
common genetic mutation is a missense mutation in cancer cells, producing 
defective protein (Cho et al., 1994). Rarely, null mutations do occur and 
research results indicate they cause a predisposition to cancer (Donhober et al., 
1992). In the formation of a tumor, expression of p53 affects the phenotype of 
cancer, and the point at which p53 shifts somatic cells to malignant tumors 
depends on the tumor type. For instance, most colorectal cancers start from 
APC mutation to undergo genetic changes in Ras, DCC (Deleted in Colorectal 
Cancer), and lastly, p53 (Levine, 1997). In normal cases, the amount of p53 
expressed in the cell is low and controlled by the degradation of protein by the 
E3 ligase (E3 ubiquitin ligase) known as MDM2, the negative regulator of 
p53 (Kubbutat et al., 1997). The mechanisms of p53 activation discovered in 
various tumors is subdivided into upstream, where p53 is activated, and 
downstream, where activated p53 affects the cells. First, there are three 
upstream pathways that can activate p53: 1) DNA damage such as ionized 
radiation, 2) abnormal growth signals such as expression of activated 
oncogenes like Ras or Myc, and 3) through other causes such as chemical 
carcinogens. The upstream activations are activated through stress on the cells, 
and inhibit the degradation of p53. However, in the downstream pathway, p53 
expresses target genes such as tumor suppressor genes that inhibit cell cycle, 
induce cell death, maintain genetic stability and block tumor angiogenesis 





1.4 Cancer and biomarkers 
 The demand for quick and accurate diagnosis is an important problem 
worldwide. Biomarkers could be used to address this problem, and if applied 
accurately for each cancer discovered, they could serve various purposes 
including diagnosis, prognosis, and the assessment of treatment effects. The 
aim of this research is to perform bioinformatics research as part of the search 
for useful biomarkers. Before providing a detailed description of the research, 
the general concepts of biomarkers are described. There are several 
definitions of biomarkers. The definition from the Biomarkers Definition 
Working Group is ‘Indicators having characteristics that can be objectively 
measured and evaluated for pathogenic processes, biological processes, and 
drug response by the treatment’ (Biomarker Definition Working Group, 2001). 
Biomarkers with these features could be applied in various fields such as 
detection of disease and monitoring of health status. Biomarker applications 
in cancer could be include quantifying the probability of carcinogenesis, early 
diagnosis, disease progression, and observation of treatment efficacy. 
Substances used as biomarkers have been expanded to more varied purposes, 
and can be generally classified as DNA, mRNA, protein, and metabolites. In 
uncovering these biomarkers, among the several methods that can be used, we 
use methods in which genome, proteome, and the metabolome are utilized. 
There are advantages and disadvantages for each method, and approach can 
be applied in multiple methods (Llyin et al., 2004). Figure 1.6 depicts the 
aforementioned methods. An examples of biomarkers used in various cancer 
diagnoses are found in Table 1.4 (Roche Diagnostics Global Tumor Marker 
Workshop, 2013). In this section, CA125 and CEA are explained in more 
detail. CA125 (Cancer Antigen 125) has been utilized as an important marker 
in diagnosis of ovarian cancer, yet in cases of women before / after 




this limitation, multiple biomarker analysis was performed and it was 
discovered that using CA125 in combination with HE4 (Human Epididymis 
protein 4) increased both sensitivity and specificity increases in women before 
/ after menopause. The use of CA125 with HE4 enhanced the accuracy of 
diagnosis, yielding more accurate results in stage 1 ovarian cancer (Moore et 
al., 2008). CEA (Carcinoembryonic Antigen), another important marker, is an 
antigen first discovered in colorectal cancer, and likely expressed in various 
cancers including stomach, breast, thyroid, pancreatic, liver, gastric, renal, 
ovarian, and cervical cancer. Due to lack of cancer specificity, CEA cannot be 
used as a marker for diagnosis or screening tests, but it can be used as a useful 
marker for predictions before surgery and assessment of treatment 
effectiveness after surgery (American Cancer Society, 2012). Furthermore, 
biomarkers detected with new technological advances will play an important 
role in the diagnosis and treatment of numerous diseases besides cancer. 
These technologies may include the development of mathematical algorithms 
to analyze many factors associated with the diagnosis of disease (Bhatt et al., 






1.5 Objective of study 
 Research into more accurate and specific biomarkers is important for 
solving the problem of cancer. This study was performed to provide useful 
information to suggest potential biomarkers for bioinformatics and the 
systems biology aspect. Two major research objectives were set, and the 
entire process was as follows.  
 First, a database that was specialized for cancer and biomarkers was 
constructed for efficient data collection and management. The constructed 
database was designed for academic utilization, and cancer-related genes 
(oncogene, proto-oncogene, tumor suppressor gene) and protein biomarkers 
were manipulated for research purposes from large public data storage. 
 Second, PPI (Protein–Protein Interaction) and GO (Gene Ontology) 
analysis were performed based on this database and other public databases. It 
is based on the hypothesis that biological pathways, molecular functions, and 
positions with interactive roles among the factors in the network of specific 
targets are important in cancer. Here, the target refers to potential markers for 
breast cancer. 
 In particular, the target candidates utilized in the target selection step 
are ones that are thought to have possibilities as biomarkers via 
experimentation. There candidates were utilized to select the highest- 
possibility targets as markers. In addition, through this analysis, the general 
characteristics of markers were expected to be discovered. For the research, 
bioinformatics analysis was performed, based on the constructed database, 










Figure 1.1 Cell cycle checkpoint and Cyclin/CDK complex. Cell cycle is composed 
of G1, S, G2, and M phases. The checkpoints located at the end of each phase of the 
cell cycle ensure transition to the next phase. Cell cycle is controlled by cyclins 







Figure 1.2 A brief schematic of cancer cell formation. Proto-oncogene is 







Figure 1.3 Mutations transform proto-oncogenes into oncogenes. To be an 
activated oncogene, a proto-oncogene needs to be mutated by the mechanisms 







Figure 1.4 Two-hit hypothesis in tumor suppressor genes. This hypothesis 
explains the mechanism of inactivation of tumor suppressor genes. If a genetic 










Figure 1.5 Differences in mutation mechanisms of oncogenes and tumor 
suppressor genes. Oncogenes and tumor suppressor genes yield the same result, such 
as unlimited cell division, through different paths. Oncogenes are related dominant 








Figure 1.6 A type of biological material that can be used as a biomarker and the 
technical method for identifying the biomarker. A biological material that serves 
as a biomarker, and the associated techniques for identifying biomarkers based on 






Table 1.1 Comparison of features of a normal cell and a cancer cell 
Features Normal cell Cancer cell 
Growth signaling Growth factor signal required Proliferative signal  sustained 
Growth suppressor 
signaling 
Receives growth suppressor 
signaling 
Evades growth suppressors 
signaling 
cell death If necessary, removed by apoptosis Resists cell death 
Replication Cell division is limited Immortal reproduction is possible 
Angiogenesis Generally maintains without creating new blood vessels Induces angiogenesis 
Metastasis Cell location is generally fixed Actively invades and metastasizes 
 
Through the comparison between cancer cell and normal cell, it can be understood the 




Table 1.2 Classification of oncogenes according to the function of proto-
oncogenes 
Classification Function Genes 
Growth factor 
Induces proliferation  
and have extracellular 
signal functions 
INT2, KGF(HST), SIS 
Growth factor 
receptor 
Enables passage of 
information from the cell 
membrane, regulates cell 
growth 
ErbB, FMS, KIT, MET,  
RET, ROS, TRK 
Signal  
transducer 
Transmits growth factor 
receptor signals  




Monomeric H-ras, K-ras, N-ras 
















Regulates the expression of 
genes in the final step of 
signal transduction 
MYC family, ErbA, ETS, 
FOS, JUN, MYB 
Other Related to apoptosis BCL2 
 
Oncogenes are classified as a function and biochemical properties of normal genes that is proto 




Table 1.3 Representative tumor suppressor genes in humans 
Gene  Function of protein Familial cancer syndrome Sporadic cancer 
RUNX3  TF co-factor - gastric carcinoma 
HRPT2  chromatin protein parathyroid tumors, jaw fibromas parathyroid tumors 





- many types 
RASSF1A  multiple functions - many types 
TGFBR2 
 




VHL  ubiquitylation of HIF 
von Hippel-Lindau 
syndrome renal cell carcinoma 












NKX3.1  homeobox TF - prostate carcinoma 
p16INK4A*  CDK inhibitor familial melanoma many types 
p14ARF  p53 stabilizer - all types 
PTC 
 receptor for 
hedgehog GF 




TSC1  inhibitor of mTOR tuberous sclerosis - 









prostate, breast, and 
thyroid carcinomas 












CDKN1C inhibitor wieddemann 
syndrome 












and lung carcinomas 
TSC2  inhibitor of mTOR tuberous sclerosis - 
CBP  TF co-activator Rubinstein-Taybi syndrome AML 
CYLD  deubiquitinating enzyme cylindromatosis - 
CDH1  cell-cell adhesion familial gastric carcinoma invasive cancers 
TP53  TF Li-Fraumeni syndrome many types 
NF1 
 




BECN1  autophagy - breast, ovarian, prostate 
PRKAR1A  subunit of PKA multiple endocrine neoplasia 
multiple 
endocrinamas 




























Expression of proteins of tumor suppressor genes have specific functions. They are related to 
various familial and sporadic cancer (Weinberg, 2006). 
*also known as MTS1, CDKN2, and p16 
†also called MMAC or TEP1 





Table 1.4 Biomarkers used in the diagnosis of cancer 
Cancer First marker Second marker 
Colorectal CEA CA19-9 
Pancreatic CA19-9 CEA 
Stomach CA72-4 CEA, CA19-9 
Esophagus CEA, SCC - 
Liver AFP - 
Gall Bladder CA19-9 - 
Breast CEA, CA15-3 - 
Ovary AFP, CA125, HE4 CA72-4 
Cervix uteri SCC CEA 
Lung 
SCLC* NSE, ProGRP CYFRA21-1 
NSCLC† CYFRA21-1 CEA, SCC 
Germ cell AFP, HCG+b - 
Prostate PSA - 
Bladder - CYFRA21-1 
Thyroid SCC, TG CEA 
C-Cell Calcitonin CEA 
ENT‡ - CEA, CYFRA21-1 
mal.Melanoma S100 - 
 
The types of the biomarkers used for diagnosis of cancer are shown (Roche Diagnostics Global 
Tumor Marker Workshop, 2013). 
*Small Cell Lung Cancer  
†Non Small Cell Lung Cancer  







MATERIALS AND METHODS 
 
2.1 Database construction 
 A database was structured for the collection and management of 
necessary data for cancer-related research. The constructed database included 
information regarding cancer-related genes such as oncogenes, proto-
oncogenes, tumor suppressor genes, and biomarker candidates of major 
cancers, as well as bioinformatics analysis tools and link sites for future usage. 
Additionally, to make information searching more convenient, various search 
functions were equipped, and a FASTA (Fast-All) file download function was 
added. It was created as a web-based database for convenient access to and 
manipulation of the data. For this, an 8C AMD Opteron-6128 2.0 Ghz, 8 Gb 
RAM, 50 Gb SATA 7200 rpm 3 Gbps HDD server was created based on the 
HPC cluster system, and Linux v2.6318 was used as the operating system. 
The information within the database came from several public databases, and 
it was then manipulated for research purposes using Java. The manipulated 
data was saved on a MySQL (My Sequel) server, and the information on the 
server was synchronized with the web using HTML (HyperText Markup 
Language), JDBC (Java Database Connectivity), and JSP (Java Server Page), 
and Tomcat v7.0 utilized as a web container. For the web-based database, the 
system development information is found in Table 2.1. 
 The database is largely composed of three parts. First, in the case of 




After gathering information about oncogenes and tumor suppressor genes 
through the NCBI (National Center for Biotechnology Information) PubMed 
data mining results by Tumor Associated Gene 
(http://www.binfo.ncku.edu.tw/TAG/GeneDoc.php), the categorized 
information on the UniProt (http://www.uniprot.org) database was utilized to 
classify the proto-oncogenes (The UniProt Consortium, 2014). In addition, the 
information about produced proteins was obtained from the UniProt database, 
and parsing that utilized Java was performed to extract information in the 
required form. The reason that the data had to be extracted in a specific form 
is that the format of information and the content provided by each public 
database was different, and thus the constructed database sought to unify and 
compile large data. Data was formed as a text file, and detailed components 
were GENE, CHROMOSOME, LOCUS, PROTEIN, LENGTH, and FASTA 
format. To provide a FASTA file with gene and protein sequence information, 
Java was utilized. The produced FASTA file included protein name, organism, 
gene name, and the protein sequence information provided by each gene, 
starting with ‘>‘ mark. The protein sequence is enumerated by capital letters, 
and breaks into a new line after each 70. The parsing process and the resulting 
FASTA file can be reviewed in Figure 2.1. 
 The previously described text file composed of GENE, 
CHROMOSOME, LOCUS, PROTEIN, LENGTH, and FASTA format is 
saved in the table produced on the MySQL open database server. The column 
format saved in this case is text, and the gene name, chromosome location, 
and the protein sequence length information were set as ‘varchar’ type, a 
variable length string. In addition, the protein name was set as ‘text’ type, 
considering that the length tends to be long, and protein sequence was set as 
the ‘longtext’ type, as they contain very long information. The gene name was 
saved as a primary key for future search in the table-making process, and null 




information regarding each produced table. Additionally, MySQL with the 
data saved, JSP as a web-programming language, and JDBC as a database 
program interface were synchronized to enable searching according to input 
query and to allow searching of the gene table with only the gene name or 
keywords. The JSP language refers to the Java Server Page; it is able to 
control the content or shape of the webpage, and can call up the Java program 
activated by a web server such as Tomcat. JDBC (Java Database Connectivity) 
functions as a link between databases to run SQL queries within the program 
coded by Java. Such a search function is necessary as it provides the 
convenience of enabling the download, and opening and/or saving 
information regarding the produced protein of each gene and the FASTA file 
of selected genes directly onto the user’s computer. Additionally, even if the 
gene’s classification information is unknown, it is still searchable, and the 
classification information is provided in the results page. 
 Next, cancer protein biomarkers and differentially expressed protein 
are explained. As the database has been designed for biomarkers, the marker 
information for various types of cancers required attention. The related 
marker data was collected utilizing EDRN (Early Detection Research 
Network) (http://edrn.nci.nih.gov/) under NCI (National Cancer Institute, 
http://www.cancer.gov/). Cancer biomarkers were categorized according to 
the material: Gene, genome, protein, proteome, and epigenome. The provided 
biomarker included ones that were not applied clinically, yet are meaningful 
markers, as suggested by researchers. Therefore, there is the advantage that it 
acquires information that has not been provided by other public databases. 
The information provided by EDRN biomarkers has been classified according 
to the applied cancer to be shown in Table 2.3. The detailed data provided by 
one marker is composed of the gene name, protein name, other aliases, 
applied cancer, and a short description. In this research, such information was 




restrained to protein, and sought to provide various information including the 
molecular function and biological process of each marker from the GO (Gene 
Ontology, http://www.geneontology.org/) database (The Gene Ontology 
Consortium 2000), and the sequence data of the UniProt was added to provide 
various information. In addition to the data explained thus far, the marker 
panel information provided by EDRN and the protein domain data of the 
classified markers by cancer type from Pfam (http://pfam.xfam.org/) database 
were parsed in Java, and then posted in the constructed database (Finn et al., 
2014). The information regarding the data parsing that utilized Java, HTML, 
MySQL, JavaScript, JSP, and Tomcat was carried out in the same way as the 
cancer-related genes previously mentioned, and were omitted. Table 2.4 
shows the MySQL column information of the produced table regarding cancer 
biomarkers. For the diversity of target candidates, DEFs (Differentially 
Expressed Proteins) through assay experiments of the dbDEPC 
(http://lifecenter.sgst.cn/dbdepc/index.do) database are also provided, as well 
as EDRN biomarkers. Only validated data were included (He et al., 2012), 
and the data processing using computer languages was the same. 
 The last part is a page related to bioinformatics research, composing a 
link site out of BLAST (Basic Local Alignment Search Tool) and other 
various analysis tools (Altschul et al., 1990). In the BLAST page, the 
standalone BLAST and the wwwblast provided by NCBI 
(http://www.ncbi.nlm.nih.gov/) were used, composed to allow the utilization 
of sequence data such as cancer-related genes and the biomarkers of each 
cancer. Additionally, various bioinformatics research–related sites used for 
analyzing this research were linked to enhance the convenience of future 




2.2 Data collection 
2.2.1 Cancer-specific network 
 In searching for breast cancer targets, various data and bioinformatics 
tools were utilized. In data collection, the constructed database for this 
research and several public databases were used, and the outline of the 
research process is shown in Figure 2.2. Protein interaction data and cancer 
genes data were necessary to form a cancer-specific network, and all data was 
gathered from public databases. First, protein interaction data was brought 
from the HIPPIE (Human Integrated Protein-Protein Interaction rEference) 
(http://cbdm.mdc-berlin.de/tools/hippie/index.php) (Release 1.5: Dec 21, 
2012), which integrates public database data regarding protein interactions, 
and provides experimental evidence of the interactions of each protein with 
scored information. It includes the HPRD (Keshava Prasad et al., 2009), 
BioGRID (Stark et al., 2011), IntAct (Aranda et al., 2010), MINT (Ceol et al., 
2009), DIP (Salwinski et al., 2004), and BIND (Bader et al., 2003) public 
databases, for 13,949 proteins and 122,708 interaction data in total, which 
were used to generate a cancer-specific network (Schaefer et al., 2012). 
 The cancer genes data for the cancer network were brought from four 
databases, and in total, 3,399 data were used. The four databases are the 
Cancer Gene Census (http://cancer.sanger.ac.uk/) (Futreal et al., 2004), 
Bushman Lab (Cancer Gene List, http://www.bushmanlab.org/links/genelists, 
accessed July 13, 2014), NCG 4.0 (http://ncg.kcl.ac.uk/) (An et al., 2014), and 
the Tumor Associated Gene database, as explained in the database 
construction process. Additionally, for verification of future research results, 
five clinical markers: CEACAM5, ERBB2, ESR1, MUC1, and PGR were 





sed July 25, 2014), FDA (Food and Drug Administration, Drugs, 
http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/uc
m083378.htm, accessed July 25, 2014), and ROCHE (Roche Diagnostics 
Global Tumor Marker Workshop, 2013). Whether the clinical markers had an 
important position in the network and gene ontology was confirmed. So far, 
data collection was explained for creating a cancer-specific network. The 
Gene Symbol of the HUGO (Human Genome Organisation) transformed by 
WebGestalt (Wang et al., 2013) and the HIPPIE protein interaction data 
corresponding to the symbol were used as final input data. 
 
2.2.2 Target candidates list 
 The possible target candidates list for breast cancer was built from two 
databases, and 210 data were used in the analysis. This includes the protein 
biomarker list of breast cancer from EDRN and experimentally validated data 
in a specific expressed protein list from dbDEPC. These data were utilized to 
select the most potent biomarker, and the IDs of the collected protein data 







2.3 Cancer-specific network analysis 
 To analyze the features of the produced network and define hub genes 
in detail, the degree, betweenness, and stress thought to be biologically 
meaningful or in cancer via previous research were decided by network 
analysis parameters (Jeong et al., 2001; Joy et al., 2005; Jonsson and Bates, 
2006; Yu et al., 2007; Vashisht and Bagler, 2012). The results of the 
respective selected parameters were ranked, and higher hub genes were 
filtered. NetworkAnalyze of Cytoscape was used in this calculation (Assenov 
et al., 2008).  
 Degree distribution Degree is one of the fundamental factors in 
determining the features of specific nodes, and is expressed as connectivity. 
From this value, it is possible to learn how many direct connections a specific 
node has with other nodes, and obtain the likelihood that a randomly selected 
node has the exact degree of k by calculating P(k), the degree distribution.  
 
As for a network with a total of N nodes, P(k) is obtained by dividing the 
number of nodes, n(k), by the degree of k with the total number of nodes, N 
(Barabasi and Oltvai, 2004).  
 Betweenness centrality This reflects the extent of influence that a 
certain node has on other nodes (Yoon et al., 2006), and it is as follows.  
 
Here, s and t are values from other nodes, not the value of the specific node n, 
and  refers to the number of shortest paths from s to t, and  refers to 
the number of specific nodes n that are in the shortest paths (Brandes, 2001). 
st st
NnkP k /)( 
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 Stress centrality This refers to the number of shortest paths passing 
through specific node n, and if the number of shortest paths is high, that node 
has a high stress value. The equation is as follows: 
 
The distribution of stress centrality provides information regarding the 
number of nodes with stress s with various values (Shimbel, 1953; Brandes, 
2001). 
 Additionally, it was reviewed whether the produced network is scale-
free nature, by seeing if the degree distribution, one of the parameters, follows 
the power-law distribution. The power-law is known to be appropriate for 
applying to network science, and following this distribution enables us to 
explain the existence of the hub. The equation is as follows:  
                         
If P(k) which is the likelihood that the selected node has the exact degree of k 
follows power-law, it is called the scale-free network, and in most cases in 
these networks, the degree exponent  has value 2–3 (Barabasi and Albert, 














2.4 Gene ontology analysis 
 If the hub genes in the cancer network were verified through network 
analysis, this time the significant GO terms regarding Biological Process (BP), 
Molecular Function (MF), and Cellular Component (CC) were determined 
through GO enrichment analysis; Gorilla (Eden et al., 2009) was utilized in 
the analysis. GO term selection was carried out in two steps: First, the ‘two 
unranked lists of genes’ mode was selected to obtain the GO terms specific to 
breast cancer. In here, the background set is the total genes in the cancer 
network, and the target set is the breast cancer–related genes. The breast 
cancer–related genes used in this process included the defect gene list that 
increases the risk of breast cancer from Cancer Research UK (Breast cancer 
genes, http://www.cancerresearchuk.org/cancer-help/type/breast- cancer/
about/risks/breast-cancer-genes, accessed July 25, 2014), the Top 20 breast 
cancer mutant gene provided by COSMIC 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) (Forbes et al., 
2011), the breast cancer–related gene list of the Genetics Home Reference 
(Breast cancer, http://ghr.nlm.nih.gov/condition/breast-cancer, accessed July 
25, 2014), and in total, 38 genes were used. The second step was to process a 
‘single ranked list of genes’ mode. It covered all genes included in the cancer 
network, and the genes with selected GO terms from breast cancer–related 
genes in the previous step were filtered to obtain the list.  
 The threshold value of the p value was set at < 0.001, and to treat the 
GO terms, the threshold value of B (the number of genes associated with 
significant GO terms) was set to one standard. Based on the prior research 
results in which the B value explains the signal (specific) and noise (non-
specific) (Vashisht and Bagler, 2012), in this research, the threshold was set 
as ≤ 100, which is the most applicable section from BP and CC. The gene list 




network was obtained from such gene ontology analysis, and these were 
considered as the specific factors of gene ontology, regardless of their location 
and roles within the network as a hub. 
 
2.5 Target selection for breast cancer 
 Utilizing the results from the cancer network analysis and gene 
ontology analysis, and selecting the target that is most likely for breast cancer, 
Venny’s Venn diagram (Oliveros, 2007) was utilized. First, the Venn diagram 
of the three groups was produced to see which parts differed among what the 
three groups shared in a group. The first group was the hub genes from the 
cancer-specific networks, the second group included genes with significant 
GO terms in breast cancer, and the third group was composed of would-be 
target candidates of breast cancer. The area formed by the hub genes, the GO 
genes, and the candidates group was decided as the area for targets that were 
specialized for breast cancer. Additionally, the area in which the previously 
mentioned breast cancer clinical markers CEACAM5, ERBB2, ESR1, MUC1, 
and PGR appear was checked for reference purposes. Therefore, new 
candidates that have potential as breast cancer markers with specificity of PPI 
and the GO terms can be selected. This process is explained briefly in Figure 
2.3. So far, the research process has been explained step-by-step. A database 
specialized in cancer and biomarkers was structured for efficient data 
management and analysis. It is the point of this research to screen high 
potential targets by applying the cancer-specific network and the gene 
ontology analysis results to the target candidates based on the constructed 
database and other public databases. The detailed contents of the research 





Figure 2.1 Java parsing process for creating FASTA files. Java s/w as 
programming language was utilized for data mining. File contents consist of '>' mark, 





























Figure 2.2 Workflow for the investigation of breast cancer-specific targets. The 
objective of this study is the specified breast cancer targets search. For this purpose, it 
tried to approach the problem in terms of bioinformatics and systems biology. It 
progressed by dividing into three detailed fields: Data collection, Network analysis, 
















                       
Figure 2.3 Target selection that utilizes the Venn diagram. To determine target 
area selection using a Venn diagram that was formed into three groups. Each group is 
composed of hub genes by the network, genes by GO terms, and candidates. The final 




Table 2.1 System development environment for webserver 
 
Linux, Apache Tomcat, MySQL and other programing languages were used in order to build 
the web-based database.  
Category Description 
System HPC cluster system 
CPU 
Master node (24 core), 
10 compute node (1 for 8 core) 
Memory 
Master node (16GB), 
10 compute node (1 for 8 GB) 
Operating system Linux 
Web server container Apache Tomcat v7.0 
DBMS MySQL v5.5.28 




Table 2.2 Schema of the cancer-related gene tables in MySQL 
Database & Field Data type Null Primary key 
oncogene    
 
gene varchar(20) NO PRI 
 
chromosome varchar(10) YES 
 
 
location varchar(20) YES 
 
 
protein text YES 
 
 
protein_length varchar(10) YES 
 
proto_oncogene 
   
 
gene varchar(20) NO PRI 
 
chromosome varchar(10) YES 
 
 
location varchar(20) YES 
 
 
protein text YES 
 
 
protein_length varchar(10) YES 
 
tumor_suppressor_gene    
 
gene varchar(20) NO PRI 
 
chromosome varchar(10) YES 
 
 
location varchar(20) YES 
 
 
protein text YES 
 
 
protein_length varchar(10) YES 
 
oncogene_fasta    
 
protein text YES 
 
 
organism varchar(20) YES 
 
 
gene varchar(20) NO PRI 
 
sequence longtext YES 
 
tumor_fasta    
 
protein text YES 
 
 
organism varchar(20) YES 
 
 
gene varchar(20) NO PRI 
 
sequence longtext YES 
 
 
The tables show oncogene, proto_oncogene, tumor_suppressor_gene, oncogene_fasta, 






Table 2.3 Description about cancer biomarkers from EDRN 
Cancer Type Panel No. 
Bladder Gene / Genomic 
 
1 / 0 
Protein / Proteomic 1 / 0 
Breast Gene / Genomic 
 
2 / 1 
Protein / Proteomic 113 / 0 
Colon 
Gene / Genomic 
 
0 / 0 
Protein / Proteomic 10 / 2 
Epigenetic 1 
Esophagus Gene / Genomic O (3) 0 / 8 
Protein / Proteomic 0 / 0 
Head and Neck Gene / Genomic 
 
6 / 0 
Protein / Proteomic 2 / 0 
Liver Gene / Genomic 
 
0 / 0 
Protein / Proteomic 9 / 0 
Lung Gene / Genomic O (12) 34 / 20 
Protein / Proteomic 103 / 2  
Ovary Gene / Genomic O (1) 1 / 1 
Protein / Proteomic 202 / 0 
Pancreas Gene / Genomic 
 
0 / 0 
Protein / Proteomic 7 / 0 
Prostate Gene / Genomic O (1) 347 / 8 
Protein / Proteomic 27 / 0 
 
EDRN supplies biomarkers data about bladder, breast, colon, esophagus, head and neck, liver, 





Table 2.4 Schema of the biomarker tables in MySQL 
Database & Field Data type Null Primary key 
Applies equally to all the tables. 
table 1 
 
cancer varchar(20) YES 
 
 
protein text YES 
 
 
organism varchar(20) YES 
 
 
gene varchar(20) NO PRI 
 




gene varchar(20) NO PRI 
 
molecular_function longtext YES 
 
 
biological_process longtext YES 
 
 
The tables show bladder, breast, colon, esophagus, head and neck, liver, lung, ovary, pancreas, 






CHAPTER  III. 
RESULTS 
 
3.1 Cancer biomarker database: BWBD 
This research performed bioinformatics analysis for investigation of 
breast cancer targets. A database to efficiently collect and manage the data 
was constructed. The constructed database was named BWBD 
(Bioinformatics With Biomarker Database), and the main page is shown in 
Figure 3.1. The details of the database are discussed below. The completed 
database can be found at http://lcbb.snu.ac.kr/BWBD/Main.html. 
 
3.1.1 Cancer-related genes 
The cancer-related genes page was composed with Allgene page, 
which show all the genes; in addition, the details pages in which oncogenes, 
proto-oncogenes, tumor suppressor genes and their specialized information 
were included. The search box for each page was separated for all the genes 
and the detailed gene categories. The user could use the search box to insert 
the first letter of the gene provided in the list of the genes from the database. 
Additionally, it is possible to search for each chromosome, too. Especially, if 
the user does not know that a gene belongs to a certain category, user can be 
provided with the category information of the gene from Allgene page. Each 
page provides information of cancer-related genes in table form, including 
oncogenes, proto-oncogenes, and tumor suppressor genes. Included are their 




protein length, protein sequence, and FASTA file download field. The 
FASTA file produced as text contains the protein name, protein sequence, 
organism information, and is downloadable to use in future research. In 
addition, the domain information of the protein produced by each gene is 
provided for the expansion of information usage. The search box and the 
FASTA download are shown in Figure 3.2, and the respective detailed pages 
are seen in Figures 3.3, 3.4, 3.5.  
 
3.1.2 Cancer biomarkers 
The cancer biomarkers page provides information by categorizing the 
protein biomarker data from EDRN of NCI; cancers included are major 
cancers such as head and neck, breast, colon, liver, lung, ovarian, pancreatic, 
and prostate cancer. For each marker, the protein name, gene name, molecular 
function, biological process, and the sequence information of the marker is 
provided. The marker’s molecular function and biological process were 
derived from the data of the GO database, and the sequence information was 
brought from the UniProt, protein public database. This page also enables 
search by gene name via a search form. Additionally, it shows the domain 
table of protein biomarkers to provide detailed family information, the 
sequence region of the domain, and E-value. If it is a cancer with marker 
panel information, it is posted to show a description of the combinations of 
markers and the components. The page with biomarkers is shown in Figure 
3.6. In the case of DEPs, the information was brought from the dbDEPC 
database. This deals with information regarding UniProt ID, organism, 
description, up / down, and ratio, only if there is the biomarker data. This is 




3.1.3 BLAST (Basic Local Alignment Search Tool) 
The BLAST page was created by connecting with the standalone 
BLAST and wwblast provided by NCBI, allowing homology analysis by 
using the local database specialized for the purpose of the user. Currently, 
oncogenes, proto-oncogenes, tumor suppressor genes, the marker protein of 
each cancer, human reference proteins, and primates proteins are listed. A 
proper BLAST program is selected for use in the search. When BLAST is 
used, if the query sequence is inserted in the search window, the user can be 
provided the search results from the local database according to homology. 
Though the BLAST tool was not used in this research, it is widely used for 
bioinformatics analysis. Therefore, it was included in the database design 
stage. The page could be seen in Figure 3.8. In addition, the link site page was 
produced, in which various bioinformatics research related sites such as GO, 
Cytoscape, and KEGG were linked to be used in other research. The next 
chapter will describe research results of utilizing various data and 






3.2 Result of cancer-specific network analysis 
3.2.1 Nature of cancer-specific network  
A cancer network was created by mapping the cancer gene ID of 3,399 
cancer genes with protein interaction data including 13,949 proteins, 122,755 
interactions. The network is composed of 2,902 proteins and 17,383 
interactions, and the biggest formed cluster which accounts for 87.9% of the 
cancer genes mapped in the network includes 2,551 proteins (node) and 
17,381 interactions (edge). The major cluster is shown in Figure 3.10.  
  To see if the produced cancer-specific network has a hub, degree 
distribution, whether the basic parameter of the network follows power-law 
distribution, was observed. The conducted log-log graph for P(k), the 
likelihood that the selected node has the exact degree of k, showed a scale-
free nature. ‘Scale-free nature’ means that there is no specific standard in 
describing the factors forming the network (Barabasi and Albert, 1999). 
Additionally, the degree exponent  value was 1.36, not the general 2–3, the 
value required to deduce that the expression pattern of hub genes is relatively 
modest and numerous (Onnela et al., 2007). The results graph is shown in 
Figure 3.11. When there are 10 or less degrees, there are 2,067 nodes, 71.2% 
of the total; 100 or more, 42, 1.4%; 200 or more, 10, 0.3%; and 300 or more, 3, 
and 0.1% of the total. This is evidence that a small number of nodes have high 
degree values. From this, the existence of a hub as a feature of a scale-free 






3.2.2 Top ranked hub genes 
 The previous section concerned the features of the cancer network. 
Based on the network features and network parameters of degree, 
betweenness, and stress, the rank of the hub gene was decided for the next 
analysis. As seen in Figure 3.11, the rank of the hub gene be considered 
according to the k value at the steep change of the P(k) through the vertical 
drop line on the graph. This is a point at which the log value of k is 1.65 or 
more. The nodes likely to be hub genes appear from this point. Therefore, to 
be used in the next ontology analysis, the top 150 genes of this point were 
filtered from three parameters, and a total of 166 hub genes were determined. 
The position of the top 150 hub genes of the cancer-specific network can be 
seen in Figure 3.12. Hub genes are the nodes marked yellow, and they are all 
included in the major cluster. TP53, RB1, and APC were included as tumor 
suppressor genes, and for oncogenes, genes such as EGFR, Src, and MYC 
were included. It was ascertained that the genes that are known to have 
important functions in cancer play their roles as hub genes in the cancer 
network created in this research. The list of 166 hub genes is given in Table 






3.3 Result of gene ontology analysis 
3.3.1 GO terms of breast cancer–related genes 
Enrichment analysis was performed to filter specific GO terms 
regarding breast cancer by gene ontology analysis. This is the process of 
obtaining GO terms regarding cancer and is more significant for breast cancer. 
All 2,902 genes of the cancer network were used as the background set, and 
38 breast cancer–related genes were used as the target set. They were filtered 
with p-value <0.001 and B≤100 as the standard. 
 The top 10 of the 100 GO terms of the biological process in enrichment 
scores are protein K6-linked ubiquitination (GO:0085020), negative 
regulation of fatty acid metabolic process (GO:0045922), Schwann cell 
development (GO:0014044), response to indole-3-methanol (GO:0071680), 
cellular response to indole-3-methanol (GO:0071681), glial cell apoptotic 
process (GO:0034349), positive regulation of metaphase/anaphase transition 
of cell cycle (GO:1902101), positive regulation of mitotic 
metaphase/anaphase transition (GO:0045842), negative regulation of 
mammary gland epithelial cell proliferation (GO:0033600), and negative 
regulation of neuroblast proliferation (GO:0007406). As for molecular 
function, when filtered by p-value and B value, there are two GO terms of the 
standard: JUN kinase kinase activity (GO:0008545) and beta-catenin binding 
(GO:0008013). In the cellular process, nine GO terms were obtained: 
BRCA1-BARD1 complex (GO:0031436), Mre11 complex (GO:0030870), 
nuclear chromosome, telomeric region (GO:0000784), BRCA1-A complex 
(GO:0070531), cell-cell adherens junction (GO:0005913), chromosome, 
telomeric regions (GO:0000781), chromosomal region (GO:0098687), PML 
body (GO:0016605), and nuclear body (GO:0016604). Table 3.2 summarizes 




3.3.2 Cancer network genes and breast cancer-specific     
GO terms 
GO enrichment analysis was performed, in which the breast cancer-
specific GO terms of each category were applied to all genes of the cancer 
network. This is the process to gain the gene list involved in cancer, especially 
more significant GO terms in breast cancer. In this instance, it was performed 
in a single ranked list of modes, filtered with p-value <0.001 and B≤100 as 
standard. Genes with specific GO terms of the biological process total 477 of 
2,902 genes of the cancer network. This list includes ABL1, APC, BAD, 
EGFR, EP300, ERBB2/3/4, ESR1/2, FAS, FGFR1/2/3, FOS, JUN, KRAS, 
MUC1, MYC, NF1, and TP53. Molecular function showed 11 results: APC, 
AR, BTRC, CDH1, EP300, ESR1, GSK3B, HDAC6, PXN, SMAD3, and 
VCL. In the cellular component, 55 genes were identified in the results, 
including ATM, CDK2, CHEK1/2, MAX, PML, PTEN, RB1, SKIL, TP53, 
and XPO1. As a result, 499 genes were filtered as cancer-related genes with 
breast cancer-specific GO terms. For breast cancer target selection with 210 
possible target candidates, 166 hub genes and 499 breast cancer-specific GO 





3.4 Result of target selection for breast cancer 
To select the breast cancer target, the final research goal, the data 
obtained so far were expressed in a Venn diagram. Three groups were created: 
the hub genes group, specific GO genes group, and possible target candidates 
group. The result of the Venn diagram can be seen in Figure 3.12, and the area 
for target selection is shown as the hatched region. This field was set to filter 
targets that show breast cancer specificity in the PPI network and gene 
ontology by reflecting the hypothesis of this research. A total of 34 genes 
were selected, and the results are as follow.  
 Genes that function as a hub of the network were FLNB and HNRNPK, 
and genes with specific GO terms were ANXA1, CALR, CCND1, CDH1, 
CRYAB, CTBP1, EIF3E, ERBB3, FAS, G3BP1, HSPB1, JUNB, KIT, 
MAP2K1, MUC1, PFN1, PGR, PRDX1, PTPRC, RHOA, and SOX2. Genes 
that show their features both in the network and gene ontology were BRCA1, 
EP300, ERBB2, ESR1, FLNA, GRB2, HSP90AB1, NPM1, PCNA, PTPN11, 
and YWHAZ. Additionally, viewing the area with five clinical markers for 
result verification, MUC1 and PGR were found in the specific GO genes field, 
and ERBB2 and ESR1 were discovered in the common field of network with 
GO. The results for the sub-network of the selected targets and the genetic 
ontological features of the 34 targets utilizing Panther 
(http://www.pantherdb.org/) (Mi et al., 2005) are shown in Table 3.3 and 
Figure 3.12, and Table 3.4, respectively. Additionally, as a result of viewing 
how the targets are shown in the cancer map of KEGG 
(http://www.genome.jp/kegg/) (Kanehisa and Goto, 2000), 12 genes were 
shown in 15 cancer pathways, and shown in Table 3.5. Detailed descriptions 





Figure 3.1 Main page of the database. This page consists of cancer-related link sites 
such as NCBI, NCI, NCC, NCIC, and cancer journals as CANCER CELL by Cell 
press, NATURE REVIEWS CANCER by Nature, etc. Submenu titles are CANCER 








Figure 3.2 Search box and downloaded FASTA files. The search box of the 
Allgene page for cancer-related genes and each detail search box for oncogenes, 
proto-oncogenes, and tumor suppressor genes. In the search results table, users can 

















Figure 3.3 Oncogene page of database. Search box only for the oncogene, this page 
includes information on 123 oncogenes. The table is composed of gene name, 
chromosome, locus, produced protein, protein length, and field of download for 






Figure 3.4 Proto-oncogene page of database. Search box only for the proto-
oncogene, this page includes information on 105 proto-oncogenes. The table is 
composed of gene name, chromosome, locus, produced protein, protein length, and 









Figure 3.5 Tumor suppressor gene page of database. Search box only for the tumor 
suppressor gene, this page includes information on 244 tumor suppressor genes. The 
table is composed of gene name, chromosome, locus, produced protein, protein length, 








Figure 3.6 Biomarker page of database. This page provides information about 
protein biomarkers for breast cancer. Data for each biomarker provides protein name, 






Figure 3.7 DEPs page of database. This page provides DEPs (Differentially 
Expressed Proteins) information for breast cancer. DEPs data was obtained only from 
assay results that are validated. The table is composed of cancer, UniProt ID, 







Figure 3.8 BLAST page of database. This page provides the BLAST tool for use 
with local databases. Lists consist of oncogene, proto-oncogene, tumor suppressor 







Figure 3.9 The major cluster that is generated as the cancer-specific network.  
This cluster consists of 2,551 nodes and 17,381 edges. The number of nodes 
corresponds to 88% of the total mapped cancer genes. The rest formed isolated nodes 






Figure 3.10 Degree distribution of cancer-specific network based on power-law 
and scale-free nature. The network degree exponent value was 1.36. The scale-free 
nature indicates the inequality of the degree distribution, such that nodes of a minority 







Figure 3.11 Top 150 hub genes from inside the major cluster. In the network, the 
location of the Top 150 hub genes is shown by the yellow node of the center, and 
these are all included in the major cluster. The small network on the upper right 

















Figure 3.12 Specific target area consisting of 34 genes. The hatched region includes 
the targets that are reflected characteristics of ontology and the network. In total, 34 
genes were selected as the final targets. ERBB2 and ESR1 are found in the GO area, and 







Figure 3.13 Sub-network for 34 target genes. This is a sub-network of only the 
target genes. Pink nodes indicate clinical markers ERBB2 and ESR1. Their 
interactions with other nodes are indicated by red lines, also the arrows indicate the 






Table 3.1 Top 150 hub genes list is composed of 166 genes 
No. Genes 
0 ~ 50  
Hub genes 
ABL1, ACTB, AKT1, ALB, APC, AR, ARF6, ATF2, ATF7IP, 
ATM, ATP1A1, BRCA1, BTRC, CASP8, CAV1, CBL, CDC42, 
CDC5L, CDK1, CDK2, CDK6, CDKN1A, CDKN2A, CHD3, 
CLTC, COPS5, CREBBP, CRK, CSNK2A1, CSNK2B, CTNNB1, 
CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5, DCUN1D1, 
DHX9, DLG4, E2F1, EEF1A1, EGFR, EIF1B, ELAVL1, ENO1, 
EP300, EPS15, ERBB2, ESR1 
51~ 100  
Hub genes 
ESR2, EWSR1, FLNA, FLNB, FLNC, FN1, FOS, FYN, GNB2L1, 
GRB2, GSK3B, H2AFX, HDAC2, HDAC3, HDAC4, HDAC6, 
HLA-B, HNRNPK, HSP90AA1, HSP90AB1, HSPA5, HSPA9, 
JUN, KAT5, LCK, LYN, MAP3K1, MAP3K7, MAPK1, MAPK14, 
MAPK3, MAPK6, MAPK8, MCC, MCM2, MDM2, MLH1, 
MTOR, MYC, NCK1, NCOA3, NCOR1, NFKB1, NFKB2, NPM1, 
NUP98, PABPC1, PCNA, PIK3R1, PIN1 
 
101 ~ 166  
Hub genes 
PLK1, PML, POT1, PPP1CA, PPP1CC, PPP2R1A, PPP2R2B, 
PRKAB1, PRKCD, PSMD2, PTN, PTPN11, PXN, RAC1, RAD21, 
RAF1, RAN, RAR, RB1, RBBP7, RELA, RPL5, RUVBL1, 
RUVBL2, SHC1, SIN3A, SIRT1, SKP1, SMAD2, SMAD3, 
SMAD4, SMARCA4, SMARCAD1, SMARCB1, SP1, SRC, 
SRRM1, STAT3, SYK, TCF3, TGFBR1, TK1, TNFRSF1A, TOP1, 
TP53, TP63, TP79, TPR, TSC22D1, TSG101, TUBB, UBE2D1, 
UBE2D2, UBE3A, UCHL5, USP7, VCL, VHL, XPO1, XRCC6, 
YBX1, YWHAB, YWHAE, YWHAQ, YWHAZ, ZBTB16  
 
This network was obtained from the degree, betweenness, and stress parameters. The total 166 
genes belong to the top rank 150. (red letter: degree 300 ↑ nodes; blue letter: degree 200 ↑ 




Table 3.2 Specific GO terms of breast cancer–related genes 




 GO:0085020 1.57E-04 78.69 BARD1, BRCA1 
 GO:0045922 4.67E-04 52.46 AKT1, BRCA1 
 GO:0014044 4.67E-04 52.46 NF1, MED12 
 GO:0071680 9.27E-04 39.35 CDH1, BRCA1 
 GO:0071681 9.27E-04 39.35 CDH1, BRCA1 
 GO:0034349 9.27E-04 39.35 TP53, RB1 
 GO:1902101 9.27E-04 39.35 RB1, PTEN 
 GO:0045842 9.27E-04 39.35 RB1, PTEN 
 GO:0033600 9.27E-04 39.35 GATA3, BRCA2 
 GO:0007406 9.27E-04 39.35 TP53, NF1 




 GO:0008545 4.67E-04 52.46 MAP2K4, MAP3K1 




 GO:0031436 1.57E-04 78.69 BARD1, BRCA1 
 GO:0030870 4.67E-04 52.46 NBN, RAD50 
 GO:0000784 9.27E-04 39.35 NBN, RAD50 
 GO:0070531 9.27E-04 39.35 BARD1, BRCA1 
 GO:0000781 3.59E-05 19.67 CHEK2, ATM, NBN, RAD50 
 GO:0098687 4.65E-05 18.52 CHEK2, ATM, NBN, RAD50 
 GO:0005913 7.72E-04 15.74 CDH1, APC, MYH9 
 GO:0016605 4.04E-06 13.12 RAD51, CHEK2, TP53, RB1, PTEN, NBN 
 GO:0016604 9.90E-04 5.02 TP53, CHEK2, RAD51, RB1, PTEN, NBN 
 
List of selected GO terms that appear specifically in breast cancer–related genes. The 
biological process is only shown for 10 of the total 100. Molecular function selected two GO 
terms, and cellular component selected nine GO terms. These have been sorted in descending 






Table 3.3 34 target genes list and presence of a clinical marker in each area 
Area Target Genes total No. Clinical marker 
Hub Genes 
  FLNB, HNRNPK 2 - 
GO Genes 
  
ANXA1, CALR, CCND1, CDH1, CRYAB, 
CTBP1, EIF3E, ERBB3, FAS, G3BP1, 
HSPB1, JUNB, KIT, MAP2K1, MUC1, 
PFN1, PGR, PRDX1, PTPRC, RHOA, SOX2 
21 MUC1, PGR 
Hub + GO Genes 
  
BRCA1, EP300, ERBB2, ESR1, FLNA, 
GRB2, HSP90AB1, NPM1, PCNA, PTPN11, 
YWHAZ 
11 ERBB2, ESR1 
 
This is a detailed list of selected targets in each area. ERBB2 and ESR1 were found in the GO 




Table 3.4 Gene ontology characteristics of the 34 target genes 
 
GO terms Description % 
Biological process 
 GO:0008152 metabolic process 25.9 
 GO:0009987 cellular process 21.2 
 GO:0065007 biological regulation 12.9 
 GO:0032502 developmental process 9.4 
 GO:0002376 immune system process 7.1 
 GO:0050896 response to stimulus 5.9 
 GO:0006915 apoptotic process 4.7 
 GO:0051179 localization 3.5 
 GO:0032501 multicellular organismal process 3.5 
 GO:0022610 biological adhesion 2.4 
 GO:0071840 cellular component organization or biogenesis 2.4 
 GO:0000003 reproduction 1.2 
Molecular function 
 GO:0005488 binding 35.4 
 GO:0003824 catalytic activity 22.9 
 GO:0001071 nucleic acid binding transcription factor activity 12.5 
 GO:0004872 receptor activity 8.3 
 GO:0005198 structural molecular activity 8.3 
 GO:0030234 enzyme regulator activity 4.2 
 GO:0000988 protein binding transcription factor activity 4.2 
 GO:0016209 antioxidant activity 2.1 
 GO:0045182 translation regulator activity 2.1 
Cellular component 
 GO:0044464 cell part 50.0 
 GO:0043226 organelle 30.0 
 GO:0032991 macromolecular complex 10.0 
 GO:0016020 membrane 10.0 
 
This GO terms belongs to the three categories of the selected targets. It has been sorted in 





Table 3.5 A list of genes that are displayed on the cancer map of KEGG 
KEGG ID Pathway Genes 
hsa05206 MicroRNAs in cancer 
BRCA1, CCND1, EP300, ERBB2, 
ERBB3, GRB2, HNRNPK, MAP2K1, 
RHOA 
hsa05205 Proteoglycans in cancer CCND1, ERBB2, ERBB3, FLNA, GRB2, MAP2K1, PTPN11, RHOA 
hsa05200 Pathways in cancer CCND1, EP300, ERBB2, GRB2, KIT, MAP2K1, RHOA 
hsa05203 Viral carcinogenesis CCND1, EP300, GRB2, HNRNPK, RHOA 
hsa05215 Prostate cancer CCND1, EP300, ERBB2, GRB2, MAP2K1 
hsa05213 Endometrial cancer CCND1, ERBB2, GRB2, MAP2K1 
hsa05211 Renal cell carcinoma EP300, GRB2, MAP2K1, PTPN11 
hsa05223 Non-small cell lung cancer CCND1, ERBB2, GRB2, MAP2K1 
hsa05220 Chronic myeloid leukemia CCND1, GRB2, MAP2K1, PTPN11 
hsa05210 Colorectal cancer CCND1, MAP2K1, RHOA 
hsa05212 Pancreatic cancer CCND1, ERBB2, MAP2K1 
hsa05219 Bladder cancer CCND1, ERBB2, MAP2K1 
hsa05218 Melanoma CCND1, MAP2K1 
hsa05216 Thyroid cancer CCND1, MAP2K1 
hsa05222 Small cell lung cancer CCND1 
 
Twelve of the 34 genes are shown in the 15 different cancer maps of the KEGG database. 
Particularly, CCND1 and MAP2K1 showed up in nearly all pathways. CCND1 is involved in 







CHAPTER  IV. 
DISCUSSION 
 
So far, research in the investigation for target genes that are likely 
candidates as breast cancer markers was performed by utilizing the PPI 
network and gene ontology information. In this section, the selected targets, 
their sub-network, features of the gene ontology, and the result of the cancer 
pathway of KEGG are to be examined more closely. 
 In clinical markers for confirming the results, MUC1 and PGR had 
breast cancer-specific GO terms, and ERBB2 and ESR1 turned out to be hub 
genes in the network and had the breast cancer-specific GO terms at the same 
time. However, CEACAM5 was not confirmed here. In the case of 
CEACAM5, because this marker is shown in various cancers it decreases in 
cancer specificity; therefore, it is omitted from the results of this research. In 
fact, CEACAM5 is an antigen first discovered in colorectal cancer, and yet it 
is expressed highly in stomach, breast, thyroid, pancreatic, liver, gastric, renal, 
ovarian, and cervical cancer, and thus could be applied to various cancers. 
 Next, the sub-network of selected targets was discussed. This was 
produced by mapping the 34 target genes ID in the protein interaction data; as 
a result, a cluster was formed among genes without FAS and PGR. FAS and 
PGR showed features according to GO terms, and do not affect the overall 
results. This is seen in Figure 3.13. Subsequently, the result according to the 
percentage of the gene ontology was discussed. In viewing the GO terms with 
the highest percentage of each category, the metabolic process (GO:0008152) 




process (GO:0044238) as sub GO terms. As for molecular function, binding 
(GO:0005488) was the highest at 35.4%, and had nucleic acid binding 
(GO:0003676), chromatin binding (GO:0003682), calcium ion binding 
(GO:0005509), and protein binding (GO:0005515) as sub GO terms. As for 
cellular component, the cell part (GO:0044464) was as high as 50%, and had 
intracellular (GO:0005622) as a sub GO term. 
 In addition, KEGG mapping was carried out on selected targets. As a 
result, 12 genes were found to be involved in the 15 pathways that directly 
relate to cancer. Especially, MAP2K1 and CCND1 were revealed in most 
cancer-related pathways. The pathway with the most genes mapped was 
MicroRNAs in cancer (hsa05206), followed by Proteoglycans in cancer 
(hsa05205), Pathways in cancer (hsa05200), Viral carcinogenesis (hsa05203), 
Prostate cancer (hsa05215), Endometrial cancer (hsa05213), Renal cell 
carcinoma (hsa05211), Non-small cell lung cancer (hsa05223), Colorectal 
cancer (hsa05210), Pancreatic cancer (hsa05212), and Bladder cancer 
(hsa05219). In other pathways associated with cancer, there are cell cycle 
(hsa04110), PI3K-Akt signaling pathway (hsa04151), Ras signaling pathway 
(hsa04014), and p53 signaling pathway (hsa04115). Cancer pathways and 
related gene lists are shown in Table 3.5. 
 Finally, limitations and utilization of the study are to be discussed. The 
target of specific diseases, such as biomarkers must be supported by 
experimental and clinical application, and predicting them among many 
associated factors is a hard task. For this purpose, utilizing the advantage 
provided by bioinformatics is important. The analyzed results through this 
research could be used for understanding the interactions among genes in 
carcinogenesis, the features of the formed network, the molecular functions, 
and biological pathways, and explain the common features among markers. 
These data would be able to provide useful information in creating a 




new drugs; they can also contribute to the selection of new markers by 
applying method to various cancers other than breast cancer. Moreover, the 
database for this research may be used effectively. In the database, there is 
important possible biomarker data for head and neck, colon, liver, lung, 
ovarian, pancreatic, and prostate cancer, and cancer-related gene data such as 
oncogenes, proto-oncogenes, and tumor suppressor genes. The data is 
searchable by gene type, chromosomes, and cancer type. To increase the 
convenience of searching, the database is equipped with various search 
functions. Additionally, BLAST and other bioinformatics tools were linked on 
the page, improving the convenience of the utilization. If such research is 
continued, the unsolved task of finding the solution to cancer would be 
assisted, and for this purpose, continued supplement and effort of the 





CHAPTER  V. 
CONCLUSION AND SUMMARY 
 
5.1 Conclusion 
Advances in molecular biology have resulted in significant progress in 
cancer research and serve as a foundation for research in many fields. The 
present research sought to derive useful information through accumulated 
molecular biological data and analysis. Bioinformatics technology was 
applied, and various data that is used in the research was manipulated. Using 
this data, the proposed database was constructed. The outcome of the research 
was the selection of possible targets that reflect the features of breast cancer 
by analysis of bioinformatics and systems biology.  
 The reason for this approach is that biological process, molecular 
function of cancer genes, and their interaction of network were considered 
important in the expression of cancer. In addition, since research such as 
network analysis is being widely pursued, the construction of related data 
offers a good foundation for this research. By mapping the cancer gene ID on 
protein–protein interaction data, the network and interaction information 
specialized for cancer was obtained. Through this produced network, the 
extent of the interaction of central factors and how important they are can be 
determined. In addition, the detailed role, position, and pathways were 
identified by GO enrichment analysis. Finally, by referring to the analysis 






 In this research, the basic concepts of cancer and the necessity of 
biomarkers were reviewed, and bioinformatics analysis was applied to provide 
useful information to find targets as proper biomarkers to solve the problem of 
cancer. Breast cancer was selected as the type of cancer, and network analysis 
and gene ontology analysis were performed to explore the systems biological 
features of specific targets. The analysis is based on the hypothesis that 
markers are important in gene ontology and cancer network, and that there 
will be features common to these. In addition, by utilizing candidates 
considered possible breast cancer biomarkers by experiments, the research 
sought to select targets that are more potent.  
 First, for efficient data management and analysis, a research-based 
database was construed. For this, oncogenes, proto-oncogenes, and tumor 
suppressor genes as cancer-related gene data, and biomarker data were 
brought from public databases such as NCBI, UniProt, and EDRN (NCI). 
Then, data was manipulated by Java s/w to achieve an integrated format. In 
addition, by saving these data on a MySQL server, efficiency in searching and 
data download services such as FASTA file were made possible; for this 
purpose, various search forms were equipped to the database. Computer 
languages used for the database construction were HTML Java, JavaScript, 
and JSP, and Tomcat was utilized for the web container. This database, 
specialized for cancer and biomarkers, was divided into three parts: cancer-
related genes, biomarkers, and bioinformatics tool pages such as BLAST. For 
target search research, various data and bioinformatics tools were utilized 
based on the constructed database. To create a cancer network, protein 
interaction data and cancer gene data were needed; accordingly, 13,949 
proteins, 122,708 interactions, and 3,399 cancer genes list were used. Next, 




the cancer network were used. Additionally, five markers used clinically for 
breast cancer were included in the research to see if they are important in 
network and gene ontology, and to verify future research results. 
 The produced network has 2,902 proteins and 17,383 interactions, and 
the largest cluster includes 2,551 proteins and 17,381 interactions. To see if 
the produced network has hub genes, it was checked whether the degree 
distribution, the basic parameter that reflects on the features of the network, 
follows power-law distribution. In drawing the log-log graph against the 
degree k and P(k) value, which gives the possibility that a random node would 
have the degree of k, it was discovered that it follows the power-law 
distribution. It is possible that such a scale-free network could explain the 
existence of the hub, and it can be seen that the produced network contains 
hub genes. Therefore, to decide on the proper hub genes ranking, degree 
distribution and betweenness, and stress centrality were calculated, as a result, 
166 genes listed as top 150 hub genes were obtained. Subsequently, by 
performing gene ontology analysis, more important GO terms were filtered in 
breast cancer compared to general cancer. These GO terms included negative 
regulation of neuroblast proliferation (GO:0007406) and protein K6-linked 
ubiquitination (GO:0085020) in BP; beta-catenin binding (GO:0008013) and 
JUN kinase kinase activity (GO:0008545) in MF; and nuclear chromosome, 
telomeric region (GO:0000784), cell-cell adherens junction (GO:0005913) 
and BRCA1-A complex (GO:0070531) in CC. By applying them to cancer 
network genes, a 499 GO genes list with specific GO terms of breast cancer 
was obtained. To select targets for breast cancer as the final goal of the 
research by utilizing all the performed analysis results, the hub genes, specific 
GO genes, target candidates were expressed in a Venn diagram. The common 
fields formed among the three groups were set as the field for target selection; 
thereby, the targets that reflected the features of PPI network and gene 




checked, since they were shown as the hypothesis; the verification of the 
research was shown as well. As the result, FLNB and HNRNPK (Hub genes); 
ANXA1, CALR, CCND1, CDH1, CRYAB, CTBP1, EIF3E, ERBB3, FAS, 
G3BP1, HSPB1, JUNB, KIT, MAP2K1, MUC1, PFN1, PGR, PRDX1, 
PTPRC, RHOA, and SOX2 (GO genes); and BRCA1, EP300, ERBB2, ESR1, 
FLNA, GRB2, HSP90AB1, NPM1, PCNA, PTPN11, and YWHAZ (Hub and 
GO genes) were selected as targets. This result could be useful information in 
experimental, clinical research to decide on new breast cancer markers. 
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바이오인포매틱스 기법을 활용한 유방암  
타겟 유전자 탐색 연구 
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바이오인포매틱스 전공 
 
암이라는 질병은 전 세계적으로 여전히 문제가 되고 있으며, 시급한 
해결이 요구되는 질병이다. 암을 대상으로 한 수 많은 연구가 
이루어져 왔고, 많은 진단법과 치료법들이 제시되어 왔지만 
현재까지 완전한 해결책은 없는 실정이다. 바이오마커 역시 
암이라는 질병이 가지는 문제점들에 대한 하나의 해결책으로 
유용하게 사용되고 있고, 새로운 마커를 발견하기 위한 연구가 
다방면으로 이루어지고 있다. 이러한 연구에서, 바이오인포매틱스는 
마커로서의 타겟을 발견하기 위해 암과 관련된 네트워크 및 유전자 
온톨로지 분석에 사용될 수 있다. 암은 유형별로 특성이 다르고, 
임상적으로도 접근방법이 다르기 때문에 본 연구에서는 
유방암이라는 하나의 암을 대상으로 한정하여 진행하였다. 먼저, 
효율적인 데이터 관리와 분석 기반 마련을 위해 암과 바이오마커에 
특화된 데이터베이스를 구축하였다. 데이터베이스 구축에 필요한 
데이터는 NCBI, NCI, UniProt과 같은 여러 대규모 공공 
저장소로부터 가져왔으며, Html, Java, JavaScript, MySQL, JSP 
등의 프로그래밍 언어들을 활용하여 목적에 맞게 가공하였다. 
다음으로 수집된 데이터들을 활용하여 암 네트워크를 생성하였다. 




시킴으로써 생성되었으며, 생성된 네트워크가 scale-free nature를 
가지는지 확인하기 위해 degree distribution의 멱함수(power-law) 
분포 여부를 살펴보았다. 그 결과 생성된 암 네트워크가 멱함수 
분포를 보임으로써 hub의 존재를 확인할 수 있었으며, 그래프 
특성을 반영하여 hub genes의 rank를 결정하였다. 이에 따라 
degree distribution, betweenness centrality, stress centrality와 
같은 네트워크 파라미터를 계산하여 Top 150의 hub genes을 
얻었다. 다음 분석으로 유방암 관련 주요 유전자들과 암 네트워크를 
형성하는 2,902개의 유전자들을 활용한 GO enrichment analysis를 
수행하여 유방암의 특성을 반영한 specific GO terms을 
필터링하였다. 이를 암 네트워크의 2,902개의 유전자에 적용시켜 
결과적으로 암 네트워크에 관여하면서 특히, 유방암 specific GO 
terms를 가지는 유전자 리스트를 얻었다. 분석의 마지막 단계에서 
PPI network analysis와 GO enrichment analysis로 획득된 
유전자들과 타겟 후보자들이 형성하는 Venn diagram 분석을 통해 
타겟이 선정되었으며, 여기에는 임상에서 사용되고 있는 마커 다섯 
개에 대한 결과가 참조되었다. 최종적으로 유방암의 임상 마커들과 
유사한 특성을 가지면서 PPI network와 GO에서 유의하게 나타나는 
34개의 유전자가 타겟으로서 선별되었으며, 이들이 다음 유방암 
마커 후보로서 우선적으로 이용될 수 있으리라 기대하는 바이다. 
또한 이러한 방법이 마커를 결정하는데 있어 잠정적인 후보자를 
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